Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous system

Journal of NeuroVirology

Volumn 20, Issue 1, 2014, Pages 39-53

  Akay, Cagla ^a   Cooper, Michael ^a   Odeleye, Akinleye ^a   Jensen, Brigid K ^a   White, Michael G ^a   Vassoler, Fair ^b   Gannon, Patrick J ^a   Mankowski, Joseph ^c   Dorsey, Jamie L ^c   Buch, Alison M ^a   Cross, Stephanie A ^b   Cook, Denise R ^b   Peña, Michelle Marie ^a   Andersen, Emily S ^d   Christofidou Solomidou, Melpo ^d   Lindl, Kathryn A ^a   Zink, M Christine ^c   Clements, Janice ^c   Pierce, R Christopher ^b   Kolson, Dennis L ^b   Jordan Sciutto, Kelly L ^a   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Antiretroviral; Fumaric acid ester; HIV; HIV associated neurocognitive disorder; Macaque; Oxidative Stress; Reactive oxygen species; SIV

Indexed keywords

ATAZANAVIR; FUMARIC ACID METHYL ESTER; INTEGRASE INHIBITOR; L 870812 A; L 870812A; REACTIVE OXYGEN METABOLITE; SAQUINAVIR; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRESS; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; HIV ASSOCIATED DEMENTIA; IN VITRO STUDY; IN VIVO STUDY; NERVE CELL NECROSIS; NERVE INJURY; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

AIDS DEMENTIA COMPLEX; ANIMALS; ANTI-RETROVIRAL AGENTS; BLOTTING, WESTERN; BRAIN; CELL DEATH; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; MACACA; MALE; NEURONS; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84896698109     PISSN: 13550284     EISSN: 15382443     Source Type: Journal    
DOI: 10.1007/s13365-013-0227-1     Document Type: Article

References (63)

1. Akay C, Lindl KA, Shyam N, Nabet B, Goenaga-Vazquez Y, Ruzbarsky J, Wang Y, Kolson DL, Jordan-Sciutto KL (2011a) Activation status of integrated stress response pathways in neurons and astrocytes of HAND cortex. Neuropathol Appl Neurobiol 118(6):1113-1123
2. Akay C, Lindl KA, Wang Y, White MG, Isaacman-Beck J, Kolson DL, Jordan-Sciutto KL (2011b) Site-specific hyperphosphorylation of pRb in HIV-induced neurotoxicity. Mol Cell Neurosci 47:154-165
3. Ances BM, Roc AC, Korczykowski M, Wolf RL, Kolson DL (2008) Combination antiretroviral therapy modulates the blood oxygen level-dependent amplitude in human immunodeficiency virus-seropositive patients. J Neurovirol 14:418-424
4. Anderson PL, Rower JE (2010) Zidovudine and lamivudine for HIV infection. Clin Med Rev Ther 2:a2004
5. Anonymous (2011) Trial watch: phase III success for Biogen's oral multiple sclerosis therapy. Nature Reviews Drug Discovery 10:404
6. Anthonypillai C, Sanderson RN, Gibbs JE, Thomas SA (2004) The distribution of the HIV protease inhibitor, ritonavir, to the brain, cerebrospinal fluid, and choroid plexuses of the guinea pig. J Pharmacol Exp Ther 308:912-920
7. Anthonypillai C, Gibbs J, Thomas S (2006) The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses. Cerebrospinal Fluid Res 3:1
8. Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentré F, Taburet A-M (2010) Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin Pharmacokinet 49:17-45. doi: 10.2165/11318110-000000000-000000000
9. Busidan Y, Dow-Edwards DL (1999) Neurobehavioral effects of perinatal AZT exposure in Sprague-Dawley adult rats. Neurotoxicol Teratol 21:359-363
10. Chen C, Kong AN (2004) Dietary chemopreventive compounds and ARE/EpRE signaling. Free Radic Biol Med 36:1505-1516
11. Cross SA, Cook DR, Chi AW, Vance PJ, Kolson LL, Wong BJ, Jordan-Sciutto KL, Kolson DL (2011) Dimethyl fumarate, an immune modulator and inducer of the antioxidant response, suppresses HIV replication and macrophage-mediated neurotoxicity: a novel candidate for HIV neuroprotection. J Immunol 187:5015-5025
12. Cui L, Locatelli L, Xie MY, Sommadossi JP (1997) Effect of nucleoside analogs on neurite regeneration and mitochondrial DNA synthesis in PC-12 cells. J Pharmacol Exp Ther 280:1228-1234
13. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ (1999) Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS (London, England) 13:1249-1253
14. du Plooy M, Viljoen M, Rheeders M (2011) Evidence for time-dependent interactions between ritonavir and lopinavir/ritonavir plasma levels following P-glycoprotein inhibition in Sprague-Dawley rats. Biol Pharm Bull 34:66-70
15. Edén A, Fuchs D, Hagberg L, Nilsson S, Spudich S, Svennerholm B, Price RW, Gisslén M (2010) HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis 202:1819-1825
16. Fontes TM, Nakamura MU, Mattar R, Simoes RS, Wagner A, de Carvalho AM, Espiridiao S, Kulay L Jr (2011) Effects of the association zidovudine plus ritonavir on the liver and kidneys of pregnant rats. Morphological and biochemical aspects. Clin Exp Obstet Gynecol 38:126-130
17. Gannon P, Khan MZ, Kolson DL (2011) Current understanding of HIV-associated neurocognitive disorders pathogenesis. Curr Opin Neurol 24:275-283
18. Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C, Pillay D, Hill T, Johnson M, Gilson R, Anderson J, Easterbrook P, Bansi L, Orkin C, Ainsworth J, Palfreeman A, Gompels M, Phillips AN, Sabin CA (2011) Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease. Neurology 76:693-700
19. Gupta RG, Kelly KM, Helke KL, Queen SE, Karper JM, Dorsey JL, Brice AK, Adams RJ, Tarwater PM, Kolson DL, Mankowski JL (2010) HIV and SIV induce alterations in CNS CaMKII expression and activation: a potential mechanism for cognitive impairment. Am J Pathol 176:2776-2784
20. Hazuda DJ, Young SD, Guare JP, Anthony NJ, Gomez RP, Wai JS, Vacca JP, Handt L, Motzel SL, Klein HJ, Dornadula G, Danovich RM, Witmer MV, Wilson KA, Tussey L, Schleif WA, Gabryelski LS, Jin L, Miller MD, Casimiro DR, Emini EA, Shiver JW (2004) Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 305:528-532
21. Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75:2087-2096
22. Huisman MT, Smit JW, Wiltshire HR, Beijnen JH, Schinkel AH (2003) Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir. J Pharmacol Exp Ther 304:596-602
23. Kageyama M, Namiki H, Fukushima H, Terasaka S, Togawa T, Tanaka A, Ito Y, Shibata N, Takada K (2005) Effect of chronic administration of ritonavir on function of cytochrome P450 3A and P-glycoprotein in rats. Biol Pharm Bull 28:130-137
24. Krieger S (2011) Multiple sclerosis therapeutic pipeline: opportunities and challenges. Mt Sinai J Med 78:192-206
25. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ (2008) Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65:65-70
26. Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, Zeng W, Hronowsky X, Buko A, Chollate S, Ellrichmann G, Bruck W, Dawson K, Goelz S, Wiese S, Scannevin RH, Lukashev M, Gold R (2011) Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134:678-692
27. Lledo-Garcia R, Nacher A, Casabo VG, Merino-Sanjuan M (2011) A pharmacokinetic model for evaluating the impact of hepatic and intestinal first-pass loss of saquinavir in the rat. Drug Metab Dispos 39:294-301
28. Mak IT, Kramer JH, Chen X, Chmielinska JJ, Spurney CF, Weglicki WB (2013) Mg-supplementation attenuates ritonavir-induced hyperlipidemia, oxidative stress and cardiac dysfunction in rats. Am J Physiol Regul Integr Comp Physiol 305(10):R1102-R1111. doi: 10.1152/ajpregu.00268.2013
29. Manda VK, Mittapalli RK, Bohn KA, Adkins CE, Lockman PR (2010) Nicotine and cotinine increases the brain penetration of saquinavir in rat. J Neurochem 115:1495-1507
30. Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, Ellis RJ, Rodriguez B, Coombs RW, Schifitto G, McArthur JC, Robertson K (2009) Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS (London, England) 23:1359-1366
31. Mielke MM, Bandaru VV, McArthur JC, Chu M, Haughey NJ (2010) Disturbance in cerebral spinal fluid sphingolipid content is associated with memory impairment in subjects infected with the human immunodeficiency virus. J Neurovirol 16:445-456
32. Ngondi JL, Oben J, Forkah DM, Etame LH, Mbanya D (2006) The effect of different combination therapies on oxidative stress markers in HIV infected patients in Cameroon. AIDS Res Ther 3:19
33. Nolan D, Mallal S (2004) Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms. Antivir Ther 9:849-863
34. O'Donnell LA, Agrawal A, Jordan-Sciutto KL, Dichter MA, Lynch DR, Kolson DL (2006) Human immunodeficiency virus (HIV)-induced neurotoxicity: roles for the NMDA receptor subtypes. J Neurosci 26:981-990
35. Pistell PJ, Gupta S, Knight AG, Domingue M, Uranga RM, Ingram DK, Kheterpal I, Ruiz C, Keller JN, Bruce-Keller AJ (2010) Metabolic and neurologic consequences of chronic lopinavir/ritonavir administration to C57BL/6 mice. Antiviral Res 88:334-342
36. Power C, Boisse L, Rourke S, Gill MJ (2009) NeuroAIDS: an evolving epidemic. Can J Neurol Sci 36:285-295
37. Reyskens KM, Essop MF (2013a) HIV protease inhibitors and onset of cardiovascular diseases: a central role for oxidative stress and dysregulation of the ubiquitin-proteasome system. Biochim Biophys Acta 6:691-700
38. Reyskens KM, Essop MF (2013b) The maladaptive effects of HIV protease inhibitors (lopinavir/ritonavir) on the rat heart. Int J Cardiol 168:3047-3049
39. Reyskens KM, Fisher TL, Schisler JC, O'Connor WG, Rogers AB, Willis MS, Planesse C, Boyer F, Rondeau P, Bourdon E, Essop MF (2013) Cardio-metabolic effectsof HIV protease inhibitors (lopinavir/ritonavir). PLoS One 8:e73347
40. Robertson K, Liner J, Meeker RB (2012) Antiretroviral neurotoxicity. J Neurovirol 18:388-399
41. Rodriguez-Pallares J, Parga J, Joglar B, Guerra M, Labandeira-Garcia J (2009) The mitochondrial atp-sensitive potassium channel blocker 5-hydroxydecanoate inhibits toxicity of 6-hydroxydopamine on dopaminergic neurons. Neurotox Res 15:82-95
42. Shibata N, Gao W, Okamoto H, Kishida T, Yoshikawa Y, Takada K (2002) In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats. J Pharm Pharmacol 54:221-229
43. Smurzynski M, Wu K, Letendre S, Robertson K, Bosch RJ, Clifford DB, Evans S, Collier AC, Taylor M, Ellis R (2011) Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS (London, England) 25:357-365, 310.1097/QAD.1090b1013e32834171f32834178
44. Thrivikraman KV, Huot RL, Plotsky PM (2002) Jugular vein catheterization for repeated blood sampling in the unrestrained conscious rat. Brain Res Brain Res Protocol 10:84-94
45. Touzet O, Philips A (2010) Resveratrol protects against protease inhibitor-induced reactive oxygen species production, reticulum stress and lipid raft perturbation. AIDS (London, England) 24:1437-1447
46. Tozzi V, Balestra P, Salvatori MF, Vlassi C, Liuzzi G, Giancola ML, Giulianelli M, Narciso P, Antinori A (2009) Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. JAIDS J Acquir Immune Defic Syndr 52:56-63. doi: 10.1097/QAI.1090b1013e3181af1083d1096
47. Tsai CC, Follis KE, Beck TW, Sabo A, Bischofberger N, Dailey PJ (1997) Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques. AIDS Res Hum Retrovir 13:707-712
48. Vidal F, Gutierrez F, Gutierrez M, Olona M, Sanchez V, Mateo G, Peraire J, Vilades C, Veloso S, Lopez-Dupla M, Domingo P (2010) Pharmacogenetics of adverse effects due to antiretroviral drugs. AIDS Rev 12:15-30
49. Wagner A, Nakamura MU, Simoes RS, Oliveira-Filho RM, Fontes TM, de Carvalho LP, Espiridiao S, Kulay L Jr (2011) Chronic action of association of zidovudine, lamivudine and ritonavir on pregnant rats. A biologic assay. Clin Exp Obstet Gynecol 38:28-32
50. Wang Y, White MG, Akay C, Chodroff RA, Robinson J, Lindl KA, Dichter MA, Qian Y, Mao Z, Kolson DL, Jordan-Sciutto KL (2007) Activation of cyclin-dependent kinase 5 by calpains contributes to human immunodeficiency virus-induced neurotoxicity. J Neurochem 103:439-455
51. Wang Y, Shyam N, Ting JH, Akay C, Lindl KA, Jordan-Sciutto KL (2010) E2F1 localizes predominantly to neuronal cytoplasm and fails to induce expression of its transcriptional targets in human immunodeficiency virus-induced neuronal damage. Neurosci Lett 479:97-101
52. Waring JF, Ciurlionis R, Marsh K, Klein LL, Degoey DA, Randolph JT, Spear B, Kempf DJ (2010) Identification of proteasome gene regulation in a rat model for HIV protease inhibitor-induced hyperlipidemia. Arch Toxicol 84:263-270
53. Werth JL, Zhou B, Nutter LM, Thayer SA (1994) 2′,3′- Dideoxycytidine alters calcium buffering in cultured dorsal root ganglion neurons. Mol Pharmacol 45:1119-1124
54. White MG, Wang Y, Akay C, Lindl KA, Kolson DL, Jordan-Sciutto KL (2011) Parallel high throughput neuronal toxicity assays demonstrate uncoupling between loss of mitochondrial membrane potential and neuronal damage in a model of HIV-induced neurodegeneration. Neurosci Res 70:220-229
55. Wilcox KS, Buchhalter J, Dichter MA (1994) Properties of inhibitory and excitatory synapses between hippocampal neurons in very low density cultures. Synapse 18:128-151
56. Wynn HE, Brundage RC, Fletcher CV (2002) Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs 16:595-609
57. Xu J, Ikezu T (2009) The comorbidity of HIV-associated neurocognitive disorders and Alzheimer's disease: a foreseeable medical challenge in post-HAART era. J NeuroImmune Pharm 4:200-212
58. Yang Y, Dahly-Vernon AJ, Blomme EA, Lai-Zhang J, Kempf DJ, Marsh KC, Harrington YA, Nye SH, Evans DL, Roman RJ, Jacob HJ, Waring JF (2010) Liver transcriptomic changes associated with ritonavir-induced hyperlipidemia in sensitive and resistant strains of rats. Vet J 185:75-82
59. Yilmaz A, Ståhle L, Hagberg L, Svennerholm B, Fuchs D, Gisslén M (2004) Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen. Scand J Infect Dis 36:823-828
60. Yilmaz A, Gisslen M, Spudich S, Lee E, Jayewardene A, Aweeka F, Price RW (2009) Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One 4:e6877
61. Zhao S, Zhang Y, Gu Y, Lewis DF, Wang Y (2004) Heme oxygenase-1 mediates up-regulation of adhesion molecule expression induced by peroxynitrite in endothelial cells. J Soc Gynecol Investig 11:465-471
62. Zink MC, Suryanarayana K, Mankowski JL, Shen A, Piatak M Jr, Spelman JP, Carter DL, Adams RJ, Lifson JD, Clements JE (1999) High viral load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis. J Virol 73:10480-10488
63. Zink MC, Brice AK, Kelly KM, Queen SE, Gama L, Li M, Adams RJ, Bartizal C, Varrone J, Rabi SA, Graham DR, Tarwater PM, Mankowski JL, Clements JE (2010) Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA. J Infect Dis 202:161-170